Active Biotech AB Interim report January - September 2014

November 5, 2014 08:30 (CET)

Laquinimod
· Teva presented new clinical safety data in RRMS patients treated with laquinimod for two or more years at joint ACTRIMS-ECTRIMS meeting
· Teva initiated clinical studies with laquinimod in primary progressive MS (PPMS) and Huntington's disease
· The ongoing US pivotal clinical study CONCERTO is continuing according to plan. Results are expected in the first half of 2016

Tasquinimod     
· The Phase III study 10TASQ10 is proceeding according to the original schedule and results are expected in the first half of 2015

ANYARA
· Only out-licensing activities are being conducted
                    
Paquinimod (57-57)  
· Only out-licensing activities are being conducted

ISI
· CD selection expected in 2015.

New share issue
· Rights issue totaling approximately SEK 225 million to be approved by the Extraordinary General Meeting on December 1, 2014

Financial summary

MSEK July - Sept.   January - Sept.   Full Year
  2014 2013   2014 2013   2013
               
Net sales 2.6 107.0   7.5 111.9   116.0
               
Operating loss -55.7 27.9   -172.8 -128.6   -209.0
               
Loss for the period -56.6 29.2   -174.5 -130.0   -212.1
               
Loss per share (SEK) -0.76 0.39   -2.33 -1.77   -2.87
(before and after dilution)              

 

For further information, please contact:

Tomas Leanderson, President and CEO
 Tel: +46 (0)46 19 20 95
 
Hans Kolam, CFO
Tel: +46 (0)46 19 20 44
 
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0)46 19 20 00
Fax: +46 (0)46 19 11 00

The report is also available at www.activebiotech.com

 

Active Biotech AB Interim report January - September 2014